Goldman Sachs’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-30,000
| Closed | -$2.79M | – | 7138 |
|
|
2021
Q4 | $2.79M | Buy |
+30,000
| New | +$1.98M | ﹤0.01% | 3958 |
|
|
2021
Q1 | – | Sell |
-16,600
| Closed | -$1.27M | – | 6477 |
|
|
2020
Q4 | $1.27M | Sell |
16,600
-2,000
| -11% | -$150K | ﹤0.01% | 4043 |
|
|
2020
Q3 | $1.39M | Sell |
18,600
-5,000
| -21% | -$333K | ﹤0.01% | 3838 |
|
|
2020
Q2 | $1.49M | Buy |
+23,600
| New | +$1.3M | ﹤0.01% | 3669 |
|
|
2020
Q1 | – | Sell |
-30,100
| Closed | -$1.37M | – | 5667 |
|
|
2019
Q4 | $1.37M | Buy |
+30,100
| New | +$1.42M | ﹤0.01% | 3922 |
|
|
2018
Q4 | – | Sell |
-100
| Closed | -$5K | – | 5830 |
|
|
2018
Q3 | $5K | Hold |
100
| – | – | ﹤0.01% | 5512 |
|
|
2018
Q2 | $4K | Sell |
100
-1,200
| -92% | -$51.6K | ﹤0.01% | 5596 |
|
|
2018
Q1 | $51K | Sell |
1,300
-83,400
| -98% | -$3.24M | ﹤0.01% | 5475 |
|
|
2017
Q4 | $2.88M | Sell |
84,700
-34,200
| -29% | -$974K | ﹤0.01% | 3487 |
|
|
2017
Q3 | $3.03M | Buy |
118,900
+75,090
| +171% | +$1.72M | ﹤0.01% | 3611 |
|
|
2017
Q2 | $739K | Buy |
43,810
+40,760
| +1,336% | +$559K | ﹤0.01% | 4735 |
|
|
2017
Q1 | $45K | Sell |
3,050
-2,540
| -45% | -$37.6K | ﹤0.01% | 6321 |
|
|
2016
Q4 | $79K | Buy |
5,590
+1,950
| +54% | +$30.2K | ﹤0.01% | 6248 |
|
|
2016
Q3 | $64K | Sell |
3,640
-4,620
| -56% | -$76.6K | ﹤0.01% | 6394 |
|
|
2016
Q2 | $141K | Buy |
8,260
+5,060
| +158% | +$90.5K | ﹤0.01% | 5940 |
|
|
2016
Q1 | $63K | Sell |
3,200
-101,960
| -97% | -$1.63M | ﹤0.01% | 6313 |
|
|
2015
Q4 | $2M | Sell |
105,160
-1,510
| -1% | -$30.8K | ﹤0.01% | 3630 |
|
|
2015
Q3 | $2.04M | Sell |
106,670
-11,650
| -10% | -$396K | ﹤0.01% | 3778 |
|
|
2015
Q2 | $5.49M | Buy |
118,320
+9,490
| +9% | +$412K | ﹤0.01% | 2873 |
|
|
2015
Q1 | $4.76M | Sell |
108,830
-24,520
| -18% | -$1.14M | ﹤0.01% | 2958 |
|
|
2014
Q4 | $4.63M | Buy |
133,350
+1,620
| +1% | +$65.8K | ﹤0.01% | 3071 |
|
|
2014
Q3 | $5.52M | Buy |
131,730
+87,380
| +197% | +$3.9M | ﹤0.01% | 2918 |
|
|
2014
Q2 | $2.6M | Buy |
44,350
+12,210
| +38% | +$769K | ﹤0.01% | 3723 |
|
|
2014
Q1 | $2.02M | Buy |
32,140
+19,740
| +159% | +$1.31M | ﹤0.01% | 3956 |
|
|
2013
Q4 | $725K | Sell |
12,400
-7,010
| -36% | -$366K | ﹤0.01% | 5017 |
|
|
2013
Q3 | $1.02M | Buy |
19,410
+3,960
| +26% | +$266K | ﹤0.01% | 4566 |
|
|
2013
Q2 | $1.19M | Buy |
+15,450
| New | +$1.26M | ﹤0.01% | 4232 |
|
Goldman Sachs's ARNA Position: Q1 2022 in Review
Goldman Sachs sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 943,716 shares — an estimated $87.7M sold.
Goldman Sachs first reported a position in ARNA in Q2 2013 and held it in 35 quarters. The position peaked at $101M in Q4 2020. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Goldman Sachs reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Goldman Sachs sold 943,716 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $87.7M.
- Goldman Sachs first reported a position in Arena Pharmaceuticals Inc in Q2 2013 and held it in 35 quarters.
- Goldman Sachs's Arena Pharmaceuticals Inc position peaked at $101M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.